Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme

Updated daily

Drug recalls

Every FDA drug recall since 2004 - 18,109 enforcement reports, newest first, with what was recalled, why, the lots and the company. Class I is the most serious.

Class IIOngoingApr 16, 2025Carvedilol TabletsCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0336-2025Class IIOngoingApr 16, 2025Ranolazine Extended-Release Tablets 1000mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0335-2025Class IIOngoingApr 16, 2025Teriflunomide TabletsCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0334-2025Class IIOngoingApr 16, 2025Solifenacin Succinate Tablets 5mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0333-2025Class IIOngoingApr 16, 2025Saxagliptin Tablets 5mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0332-2025Class IIOngoingApr 16, 2025Nitroglycerin Sublingual Tablets 0.3MGCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0331-2025Class IIOngoingApr 16, 2025Lacosamide TabletsCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0330-2025Class IIOngoingApr 16, 2025Indomethacin Extended-Release CapsulesCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0329-2025Class IIOngoingApr 16, 2025Metformin Hydrochloride Extended-Release Tablets 1000mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0328-2025Class IIOngoingApr 16, 2025Fluphenazine Hydrochloride Tablets 2.5mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0327-2025Class IIOngoingApr 16, 2025Fluphenazine Hydrochloride TabletsCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0326-2025Class IIOngoingApr 16, 2025Pravastatin Sodium Tablets 80mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0325-2025Class IIOngoingApr 16, 2025Nitroglycerin Sublingual Tablets 0.4MGCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0324-2025Class IIOngoingApr 16, 2025Rufinamide Tablets 200mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0323-2025Class IIOngoingApr 16, 2025Frovatriptan Succinate Tablets 2.5mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0322-2025Class IIOngoingApr 16, 2025Lacosamide Tablets 200mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0321-2025Class IIOngoingApr 16, 2025Gabapentin Tablets 600mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0320-2025Class IIOngoingApr 16, 2025Voriconazole Tablets 50mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0319-2025Class IIOngoingApr 16, 2025Voriconazole Tablets 200 mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0318-2025Class IIOngoingApr 16, 2025Solifenacin Succinate Tablets 10MGCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0317-2025Class IIOngoingApr 16, 2025Propafenone Hydrochloride Extended-Release Capsules 325mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0316-2025Class IIOngoingApr 16, 2025Propafenone Hydrochloride Extended-Release Capsules 225mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0315-2025Class IIOngoingApr 16, 2025Fenofibrate Capsules 67 mgCGMP DeviationsGlenmark Pharmaceuticals Inc., USA · D-0314-2025Class IITerminatedApr 16, 2025Sofosbuvir and VelpatasvirDefective Container: blister packs not properly sealed resulting in tablets being loose in the carton.Asegua Therapeutics LLC · D-0313-2025Class IIIOngoingApr 16, 2025Gabapentin CapsulesCross ContaminationSun Pharmaceutical Industries Inc · D-0312-2025Class IIIOngoingApr 16, 2025Gabapentin CapsulesCross ContaminationSun Pharmaceutical Industries Inc · D-0311-2025Class IICompletedApr 16, 2025Venlafaxine TabletsPresence of Foreign Substance: Product complaint received for the presence of foreign material embedded resembling a metal shaving in one tablet.Zydus Pharmaceuticals (USA) Inc · D-0310-2025Class IIOngoingApr 9, 2025chlorproMAZINE Hydrochloride TabletsCGMP deviations: presence of N-Nitroso-Desmethyl Chlorpromazine impurity above the recommended interim limit.Glenmark Pharmaceuticals Inc., USA · D-0309-2025Class IIOngoingApr 9, 2025Duloxetine Delayed-Release CapsulesCGMP Deviations: presence of Nitrosamine Drug Substance Related Impurity (NDSRI), N-nitroso-duloxetine, above the recommended interim limit.Breckenridge Pharmaceutical, Inc. · D-0308-2025Class IITerminatedApr 9, 2025Voriconazole TabletscGMP Deviations: Received notification from their supplier requesting they perform a recall due to the fact they repackaged the product.Amerisource Health Services LLC · D-0307-2025Class IIOngoingApr 9, 2025Atorvastatin Calcium Tablets USP 40 mgFailed dissolution specifications: lower than specificationsBiocon Pharma Inc · D-0306-2025Class IIIOngoingApr 9, 2025Tropicamide - Proparacaine - Phenylephrine - Ketorolac Sterile Ophthalmic SolutionSub-Potent Drug: The stability batch showed a subpotent result, which does not meet the product specifications of 90.0-110.0% of the label claim.Imprimis NJOF, LLC · D-0305-2025Class IIITerminatedApr 9, 2025Tolterodine Tartrate Extended-Release CapsulesFailed Dissolution Specifications: Out of specification results obtained during routine stability testing for dissolution.The Harvard Drug Group LLC dba Major Pharmaceuticals and Rugby Laboratories · D-0304-2025Class IIOngoingApr 2, 20258.4% Sodium Bicarbonate InjectionLack of Assurance of SterilityExela Pharma Sciences LLC · D-0303-2025Class IIOngoingApr 2, 2025[CORRECT FRONT PANEL] Hydrogen Peroxide Topical SolutionLabeling; Label Mixup; some bottles have an incorrect back label indicating 91% Isopropyl AlcoholConsumer Product Partners, LLC · D-0302-2025Class IOngoingApr 2, 2025SinuCleanse Soft Tip NETI POT Nasal Wash SystemMicrobial Contamination of Non-Sterile Products: Bacterial contamination with Staphylococcus aureusAscent Consumer Products Inc. · D-0301-2025Class IOngoingApr 2, 2025SinuCleanse Premixed SALINE PACKETSMicrobial Contamination of Non-Sterile Products: Bacterial contamination with Staphylococcus aureusAscent Consumer Products Inc. · D-0300-2025Class IOngoingApr 2, 2025SinuCleanse Soft Tip Squeeze Bottle Nasal Wash SystemMicrobial Contamination of Non-Sterile Products: Bacterial contamination with Staphylococcus aureusAscent Consumer Products Inc. · D-0299-2025Class IIOngoingApr 2, 2025babyganicsFailed stability specifications: during routine stability monitoring quality concerns were identified. Physical separation for ingredients was observed.Johnson, S C and Son, Inc · D-0298-2025Class IIOngoingApr 2, 2025fentaNYL Citrate PF 200 mcg/100 mLLack of Assurance of SterilityQuVa Pharma, Inc. · D-0297-2025

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.